# Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Phase 3 study in Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer (226 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Sponsor type | Academic and hospital |
| Study | Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer |
| NCT ID | NCT07892274 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Metastatic Breast Cancer (MBC); HER2-Positive Breast Cancer; Hormone Receptor-Positive Breast Cancer |
| Intervention types | drug |
| Target enrollment | 226 |
| Site countries | China |
| Posted | 2026-10-23 |
| Planned start | 2026-11-01 |
| Event | Newly registered study |
| Event date | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.
- 226 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07892274). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.